| Literature DB >> 27251704 |
Vasiliki Katsi1, Theoni Kanellopoulou2, Thomas Makris3, Petros Nihoyannopoulos1, Efrosyni Nomikou4, Dimitrios Tousoulis5.
Abstract
Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide. Preeclampsia can be resolved by delivery, and most of the proposed preventive treatment approaches are based on processes involved in placental development in early pregnancy. Yet, none of these has been established in clinical practice. Low-dose aspirin is the most promising candidate, nevertheless; while some individual randomized controlled trials showed minimal or no statistically significant benefit, recent metanalyses showed that early initiation before 16 weeks of gestation is associated with prevention of early-onset preeclampsia and reduction in prevalence of perinatal death or morbidity of pregnant women. Heparin could be an alternative antithrombotic and anti-inflammatory median to prevent preeclampsia either alone or in combination with aspirin; however, results are conflicting concerning efficacy.Entities:
Keywords: Aspirin; Heparin; Hypertension; Placental disease; Preeclampsia; Pregnancy complications
Mesh:
Substances:
Year: 2016 PMID: 27251704 DOI: 10.1007/s11906-016-0664-3
Source DB: PubMed Journal: Curr Hypertens Rep ISSN: 1522-6417 Impact factor: 5.369